Finance, Grants, Deals

Location

A French producer of therapeutic vaccines for cancer has raised €13.1 million from private and public sources in order to bring its lead product, a therapeutic human papillomavirus vaccine, into the clinic.

Location

Merck KGaA of Germany has made an agreed bid for the US service provider, Millipore Corp, in a transaction valued at $7.2 billion, including net debt. The merged company is expected to have critical mass in bioresearch and bioprocessing.

Location

Basilea Pharmaceutica Ltd has partnered its Phase 3 antifungal agent, isavuconazole, with Astellas Pharma Inc of Japan, making it eligible for an upfront payment of CHF75 million (€51 million).

Location

In a boost for the emerging field of epigenetics, privately-owned CellCentric Ltd of Cambridge, UK has negotiated access to one of its cancer discovery programmes to Takeda Pharmaceutical Company Ltd. The deal is valued at about $200 million.

Glide Pharmaceutical Technologies Ltd has raised £2.7 million in a new investment round bringing total funds raised for its needle-free delivery technology up to £10 million. The funds will be used to take its second drug product into the clinic.

Location

Novartis AG has in-licensed a new compound for the treatment of hepatitis C that is described as the first in a new class of drugs called cyclophilin inhibitors. The deal was announced on 9 February, 2010 but no financial details were disclosed.

Location

Oxford Nanopore Technologies Ltd said that it will use the proceeds of a new funding round amounting to £17.4 million to support its technology platform and in particular, its lead project in DNA sequencing.

Location

The Netherlands-based diagnostics company, Qiagen NV, has reached an agreement with Pfizer Inc to develop a companion diagnostic for its immunotherapy vaccine, which is currently in Phase 2 development.

Location

Privately-owed French pharmaceutical company, Pierre Fabre SA, has licensed exclusive rights to Abbott Laboratories to a preclinical monoclonal antibody for cancer that targets a membrane receptor known as c-Met.

Location

As those who attend medical conferences know well, biotech executives like to talk about what they do in terms of models.